Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
AssigneePDS Biotechnology Corporation
InventorsFrank Bedu-Addo, Gregory Conn, Silva K. Gandhapudi, Martin Ward, Jerold Woodward
Life of this patent
Estimating the term…
Abstract
Methods and compositions for modifying type I IFN signaling pathways in a subject comprising the administration a cationic lipid to the subject are provided. The cationic lipids comprise 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-1-(2,3-dioleoyloxy)-propyl-N, N,N-trimethyl ammonium chloride (DOTMA), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), enantiomers and combinations thereof. The compositions may further comprise one or more antigenic components, wherein such components are autologous or nonautologous.
Claims19
1-25. (canceled)
A method of inducing type I IFN gene expression in a subject comprising administering a composition comprising a cationic lipid and a pharmaceutical carrier to the subject, wherein the cationic lipid activates type I IFN signaling.
A method for stimulation of a type I IFN signaling pathway in a subject comprising administrating a composition comprising a cationic lipid and a pharmaceutical carrier, wherein the administration of the cationic lipid results in a stimulation of a type I IFN signaling pathway.
A method for treating cancer in a subject, comprising an administration of a composition comprising a cationic lipid and a pharmaceutical carrier, wherein the administration of the cationic lipid results in a stimulation of a type I IFN signaling pathway.
Dependencies are inferred from the claim text.